Replies to post #147 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

2019-2020 for the RT002 launch is actually sooner than RVNC's prior guidance of 2020. The rapid enrollment of the phase-3 efficacy trials is presumably the impetus for the more favorable guidance.

I don't recall anyone's saying recently that RT002 could be launched in 2018 insofar as the BLA won't be submitted until early 2018 at the earliest.